CTLA4 and glioblastoma: Although monotherapy with immune checkpoint inhibitors failed to show a considerable survival benefit in early clinical trials, the addition of PD-1/PD-L1 and CTLA4 inhibitors increases the activity of CAR T-cells in a murine model of glioblastoma (27).